The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
A new generation of oral direct thrombin factor Ⅱ a inhibitor AZD0837
Author(s): 
Pages: 262-267
Year: Issue:  3
Journal: World Phytomedicines

Keyword:  AZD0837抗血栓抗凝血药心房颤动;
Abstract: 凝血因子Ⅱ在凝血级联反应中处于下游的关键位置,被激活后形成凝血酶而催化纤维蛋白原产生纤维蛋白导致凝血,因此其为血栓形成的关键因素.抑制凝血酶可以延长凝血时间,减少血栓形成风险.英国AstraZeneca公司研发的新一代口服直接凝血酶因子Ⅱa抑制剂AZD0837可用于治疗和预防心房颤动引起的卒中和深静脉血栓的发生.目前已经公布的临床前、临床Ⅰ期和Ⅱ期实验数据显示,其具有优于华法林的治疗效果,因此具有...
Related Articles
No related articles found